Uric Acid as a Marker for Renal Dysfunction in Hypertensive Women on Diuretic and Nondiuretic Therapy
Autor(a) principal: | |
---|---|
Data de Publicação: | 2009 |
Outros Autores: | , , , , |
Tipo de documento: | Artigo |
Idioma: | eng |
Título da fonte: | Repositório Institucional da UNIFESP |
dARK ID: | ark:/48912/0013000011x7p |
Texto Completo: | http://dx.doi.org/10.1111/j.1751-7176.2009.00101.x http://repositorio.unifesp.br/handle/11600/31477 |
Resumo: | Hyperuricemia is a common finding in hypertensive patients, especially among those who are on diuretic therapy. However, its clinical relevance regarding cardiovascular and chronic kidney disease (CKD) has not clearly been established. the authors assessed whether, in a population of 385 hypertensive women categorized according to diuretic therapy, the stratification in quartiles by uric acid levels would identify a gradient of changes in renal function and in risk factors for cardiovascular disease. the following were evaluated: serum uric acid, glycemia, total and fractional cholesterol, triglycerides, apolipoprotein (Apo) B, Apo A-I, and C-reactive protein. Renal function was assessed by serum creatinine, albuminuria, and estimated glomerular filtration rate (eGFR) by the Modification of Diet in Renal Disease equation, whereas cardiovascular risk was estimated through the Framingham score. A total of 246 women were on diuretic therapy; 139 were taking other antihypertensive medications. There was a reduction in eGFR parallel to the increase in uric acid levels, regardless of diuretic use and without a concomitant increase in albuminuria. in both groups, higher uric acid levels translated into an increase in metabolic syndrome components, in markers of insulin resistance, triglyceride/high-density lipoprotein levels, and Apo B/Apo A-I ratios, as well as in Framingham scores. Hyperuricemia was associated with an increase in inflammatory markers only in patients on diuretic therapy. in a binary logistic regression, hyperuricemia (uric acid > 6.0 mg/dL) was independently associated with CKD (eGFR < 60 mL/min/1.73 m(2)) (odds ratio, 2.63; 95% confidence interval, 1.61-4.3; P <.001). in hypertensive women, the presence of hyperuricemia indicated a substantial degree of kidney dysfunction as well as a greater cardiovascular risk profile. |
id |
UFSP_91691937b78cc3dec00a369c9c525651 |
---|---|
oai_identifier_str |
oai:repositorio.unifesp.br/:11600/31477 |
network_acronym_str |
UFSP |
network_name_str |
Repositório Institucional da UNIFESP |
repository_id_str |
3465 |
spelling |
Uric Acid as a Marker for Renal Dysfunction in Hypertensive Women on Diuretic and Nondiuretic TherapyHyperuricemia is a common finding in hypertensive patients, especially among those who are on diuretic therapy. However, its clinical relevance regarding cardiovascular and chronic kidney disease (CKD) has not clearly been established. the authors assessed whether, in a population of 385 hypertensive women categorized according to diuretic therapy, the stratification in quartiles by uric acid levels would identify a gradient of changes in renal function and in risk factors for cardiovascular disease. the following were evaluated: serum uric acid, glycemia, total and fractional cholesterol, triglycerides, apolipoprotein (Apo) B, Apo A-I, and C-reactive protein. Renal function was assessed by serum creatinine, albuminuria, and estimated glomerular filtration rate (eGFR) by the Modification of Diet in Renal Disease equation, whereas cardiovascular risk was estimated through the Framingham score. A total of 246 women were on diuretic therapy; 139 were taking other antihypertensive medications. There was a reduction in eGFR parallel to the increase in uric acid levels, regardless of diuretic use and without a concomitant increase in albuminuria. in both groups, higher uric acid levels translated into an increase in metabolic syndrome components, in markers of insulin resistance, triglyceride/high-density lipoprotein levels, and Apo B/Apo A-I ratios, as well as in Framingham scores. Hyperuricemia was associated with an increase in inflammatory markers only in patients on diuretic therapy. in a binary logistic regression, hyperuricemia (uric acid > 6.0 mg/dL) was independently associated with CKD (eGFR < 60 mL/min/1.73 m(2)) (odds ratio, 2.63; 95% confidence interval, 1.61-4.3; P <.001). in hypertensive women, the presence of hyperuricemia indicated a substantial degree of kidney dysfunction as well as a greater cardiovascular risk profile.Universidade Federal de São Paulo, Dept Med, Div Endocrinol, São Paulo, BrazilUniversidade Federal de São Paulo, Dept Med, Div Nephrol, São Paulo, BrazilUniversidade Federal de São Paulo, Dept Med, Div Endocrinol, São Paulo, BrazilUniversidade Federal de São Paulo, Dept Med, Div Nephrol, São Paulo, BrazilWeb of ScienceFundação de Amparo à Pesquisa do Estado de São Paulo (FAPESP)Wiley-BlackwellUniversidade Federal de São Paulo (UNIFESP)Borges, Rodolfo. L. [UNIFESP]Hirota, Andrea H. [UNIFESP]Quinto, Beata M. [UNIFESP]Ribeiro, Artur B. [UNIFESP]Zanella, Maria T. [UNIFESP]Batista, Marcelo C. [UNIFESP]2016-01-24T13:52:28Z2016-01-24T13:52:28Z2009-05-01info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersion253-259http://dx.doi.org/10.1111/j.1751-7176.2009.00101.xJournal of Clinical Hypertension. Malden: Wiley-Blackwell Publishing, Inc, v. 11, n. 5, p. 253-259, 2009.10.1111/j.1751-7176.2009.00101.x1524-6175http://repositorio.unifesp.br/handle/11600/31477WOS:000266336200002ark:/48912/0013000011x7pengJournal of Clinical Hypertensioninfo:eu-repo/semantics/openAccesshttp://olabout.wiley.com/WileyCDA/Section/id-406071.htmlreponame:Repositório Institucional da UNIFESPinstname:Universidade Federal de São Paulo (UNIFESP)instacron:UNIFESP2016-01-24T11:52:28Zoai:repositorio.unifesp.br/:11600/31477Repositório InstitucionalPUBhttp://www.repositorio.unifesp.br/oai/requestbiblioteca.csp@unifesp.bropendoar:34652024-12-11T20:50:29.343175Repositório Institucional da UNIFESP - Universidade Federal de São Paulo (UNIFESP)false |
dc.title.none.fl_str_mv |
Uric Acid as a Marker for Renal Dysfunction in Hypertensive Women on Diuretic and Nondiuretic Therapy |
title |
Uric Acid as a Marker for Renal Dysfunction in Hypertensive Women on Diuretic and Nondiuretic Therapy |
spellingShingle |
Uric Acid as a Marker for Renal Dysfunction in Hypertensive Women on Diuretic and Nondiuretic Therapy Borges, Rodolfo. L. [UNIFESP] |
title_short |
Uric Acid as a Marker for Renal Dysfunction in Hypertensive Women on Diuretic and Nondiuretic Therapy |
title_full |
Uric Acid as a Marker for Renal Dysfunction in Hypertensive Women on Diuretic and Nondiuretic Therapy |
title_fullStr |
Uric Acid as a Marker for Renal Dysfunction in Hypertensive Women on Diuretic and Nondiuretic Therapy |
title_full_unstemmed |
Uric Acid as a Marker for Renal Dysfunction in Hypertensive Women on Diuretic and Nondiuretic Therapy |
title_sort |
Uric Acid as a Marker for Renal Dysfunction in Hypertensive Women on Diuretic and Nondiuretic Therapy |
author |
Borges, Rodolfo. L. [UNIFESP] |
author_facet |
Borges, Rodolfo. L. [UNIFESP] Hirota, Andrea H. [UNIFESP] Quinto, Beata M. [UNIFESP] Ribeiro, Artur B. [UNIFESP] Zanella, Maria T. [UNIFESP] Batista, Marcelo C. [UNIFESP] |
author_role |
author |
author2 |
Hirota, Andrea H. [UNIFESP] Quinto, Beata M. [UNIFESP] Ribeiro, Artur B. [UNIFESP] Zanella, Maria T. [UNIFESP] Batista, Marcelo C. [UNIFESP] |
author2_role |
author author author author author |
dc.contributor.none.fl_str_mv |
Universidade Federal de São Paulo (UNIFESP) |
dc.contributor.author.fl_str_mv |
Borges, Rodolfo. L. [UNIFESP] Hirota, Andrea H. [UNIFESP] Quinto, Beata M. [UNIFESP] Ribeiro, Artur B. [UNIFESP] Zanella, Maria T. [UNIFESP] Batista, Marcelo C. [UNIFESP] |
description |
Hyperuricemia is a common finding in hypertensive patients, especially among those who are on diuretic therapy. However, its clinical relevance regarding cardiovascular and chronic kidney disease (CKD) has not clearly been established. the authors assessed whether, in a population of 385 hypertensive women categorized according to diuretic therapy, the stratification in quartiles by uric acid levels would identify a gradient of changes in renal function and in risk factors for cardiovascular disease. the following were evaluated: serum uric acid, glycemia, total and fractional cholesterol, triglycerides, apolipoprotein (Apo) B, Apo A-I, and C-reactive protein. Renal function was assessed by serum creatinine, albuminuria, and estimated glomerular filtration rate (eGFR) by the Modification of Diet in Renal Disease equation, whereas cardiovascular risk was estimated through the Framingham score. A total of 246 women were on diuretic therapy; 139 were taking other antihypertensive medications. There was a reduction in eGFR parallel to the increase in uric acid levels, regardless of diuretic use and without a concomitant increase in albuminuria. in both groups, higher uric acid levels translated into an increase in metabolic syndrome components, in markers of insulin resistance, triglyceride/high-density lipoprotein levels, and Apo B/Apo A-I ratios, as well as in Framingham scores. Hyperuricemia was associated with an increase in inflammatory markers only in patients on diuretic therapy. in a binary logistic regression, hyperuricemia (uric acid > 6.0 mg/dL) was independently associated with CKD (eGFR < 60 mL/min/1.73 m(2)) (odds ratio, 2.63; 95% confidence interval, 1.61-4.3; P <.001). in hypertensive women, the presence of hyperuricemia indicated a substantial degree of kidney dysfunction as well as a greater cardiovascular risk profile. |
publishDate |
2009 |
dc.date.none.fl_str_mv |
2009-05-01 2016-01-24T13:52:28Z 2016-01-24T13:52:28Z |
dc.type.driver.fl_str_mv |
info:eu-repo/semantics/article |
dc.type.status.fl_str_mv |
info:eu-repo/semantics/publishedVersion |
format |
article |
status_str |
publishedVersion |
dc.identifier.uri.fl_str_mv |
http://dx.doi.org/10.1111/j.1751-7176.2009.00101.x Journal of Clinical Hypertension. Malden: Wiley-Blackwell Publishing, Inc, v. 11, n. 5, p. 253-259, 2009. 10.1111/j.1751-7176.2009.00101.x 1524-6175 http://repositorio.unifesp.br/handle/11600/31477 WOS:000266336200002 |
dc.identifier.dark.fl_str_mv |
ark:/48912/0013000011x7p |
url |
http://dx.doi.org/10.1111/j.1751-7176.2009.00101.x http://repositorio.unifesp.br/handle/11600/31477 |
identifier_str_mv |
Journal of Clinical Hypertension. Malden: Wiley-Blackwell Publishing, Inc, v. 11, n. 5, p. 253-259, 2009. 10.1111/j.1751-7176.2009.00101.x 1524-6175 WOS:000266336200002 ark:/48912/0013000011x7p |
dc.language.iso.fl_str_mv |
eng |
language |
eng |
dc.relation.none.fl_str_mv |
Journal of Clinical Hypertension |
dc.rights.driver.fl_str_mv |
info:eu-repo/semantics/openAccess http://olabout.wiley.com/WileyCDA/Section/id-406071.html |
eu_rights_str_mv |
openAccess |
rights_invalid_str_mv |
http://olabout.wiley.com/WileyCDA/Section/id-406071.html |
dc.format.none.fl_str_mv |
253-259 |
dc.publisher.none.fl_str_mv |
Wiley-Blackwell |
publisher.none.fl_str_mv |
Wiley-Blackwell |
dc.source.none.fl_str_mv |
reponame:Repositório Institucional da UNIFESP instname:Universidade Federal de São Paulo (UNIFESP) instacron:UNIFESP |
instname_str |
Universidade Federal de São Paulo (UNIFESP) |
instacron_str |
UNIFESP |
institution |
UNIFESP |
reponame_str |
Repositório Institucional da UNIFESP |
collection |
Repositório Institucional da UNIFESP |
repository.name.fl_str_mv |
Repositório Institucional da UNIFESP - Universidade Federal de São Paulo (UNIFESP) |
repository.mail.fl_str_mv |
biblioteca.csp@unifesp.br |
_version_ |
1818602553138479104 |